16.19
0.35 (2.24%)
| Previous Close | 15.83 |
| Open | 16.00 |
| Volume | 1,732,704 |
| Avg. Volume (3M) | 2,390,012 |
| Market Cap | 1,627,515,008 |
| Price / Sales | 22.63 |
| Price / Book | 1.54 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| Operating Margin (TTM) | -1,596.87% |
| Diluted EPS (TTM) | -4.61 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Total Debt/Equity (MRQ) | 14.08% |
| Current Ratio (MRQ) | 8.81 |
| Operating Cash Flow (TTM) | -351.38 M |
| Levered Free Cash Flow (TTM) | -185.90 M |
| Return on Assets (TTM) | -19.05% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Beam Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 2.13 |
|
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.22% |
| % Held by Institutions | 98.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mwg Management Ltd. | 31 Mar 2025 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 394.29%) | Buy |
| Median | 62.50 (286.16%) | |
| Low | 25.00 (Barclays, 54.46%) | Hold |
| Average | 57.50 (255.27%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 15.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 07 May 2025 | 25.00 (54.46%) | Hold | 16.23 |
| Guggenheim | 07 May 2025 | 55.00 (239.82%) | Buy | 16.23 |
| Wells Fargo | 07 May 2025 | 70.00 (332.50%) | Buy | 16.23 |
| HC Wainwright & Co. | 07 Apr 2025 | 80.00 (394.28%) | Buy | 15.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |